NanoSyrinx named as winner of the 2022 AbbVie UK Golden Ticket programme
NanoSyrinx has been named as the winner of the 2022 AbbVie UK Golden Ticket accelerator programme.
The 2022 AbbVie UK Golden Ticket is a competitive award, open to early-stage life sciences companies and biotech start-ups that are working to develop cutting-edge therapies or technology platforms. Under the programme, the company will benefit from:
One year of free lab space, funded by AbbVie, at Pioneer Group’s BioCity Nottingham site, where NanoSyrinx will have access to core facilities and services
Tailored support from AbbVie’s world-leading global and UK scientists, business leaders and mentors
Exclusive access to AbbVie and Pioneer Group’s networks over the year with the opportunity for future collaboration
NanoSyrinx CEO, Dr Joe Healey, said:
“We are incredibly proud to have been selected as the winner of the first ever AbbVie UK Golden Ticket. This award recognises the potential of our unique nanosyringe platform to address a wide range of challenges associated with the intracellular delivery of biological therapeutics. We are looking forward to engaging more deeply with the experts from AbbVie and accessing the support of Pioneer Group as we move forward with building our internal pipeline”
The Award was announced today by Belinda Byrne, PhD, AbbVie’s Medical Director in the UK, who said:
“Part of what drives me and excites me about the industry that I work in is the opportunity to make a difference for patients. Supporting discovery science is that very early stage of identifying novel targets of disease, new compounds that may be able to treat a disease, or new ways of getting drugs to exactly where they need to be to treat a particular condition […]
Through the Golden Ticket programme, we have seen some of the fantastic cutting edge science taking place in the UK and are proud to have the opportunity to work with our inaugural winner – NanoSyrinx – to support the development of its novel drug delivery technology.”
For more information, see the announcement here.